Blog
Plain language articles on research peptides: new studies, regulatory shifts, and practical safety. Educational only, and never medical advice.
Retatrutide side effects 2026: what phase 3 trials show
Retatrutide side effects from the new phase 3 trials: nausea rates by dose, the tingling skin effect called dysesthesia, heart rate, and who quit.
6 min readSafePeptideUse
Read article →BPC-157 human trials 2026: the first US placebo study
BPC-157 human trials are finally starting in the US. What the new Arkansas study will test, when results could land, and what human data exists today.
5 min readSafePeptideUse
Empower Pharmacy warning letter: what it means in 2026
The FDA warned Empower Pharmacy over compounded tirzepatide and semaglutide. What the letter says, whether compounded GLP-1s are still legal, and what to check.
5 min readSafePeptideUse
Retatrutide in 2026: new phase 3 data and a closing access window
The strongest weight loss numbers yet landed this year, at the same time a court fight over what retatrutide legally is threatens to end research and compounded access. Here is what the evidence shows and what is actually changing.
4 min readSafePeptideUse
Where peptide compounding rules stand after the 2026 FDA votes
The FDA spent 2026 deciding which bulk peptides pharmacies may compound. Here is what changed, what the July advisory votes did, and why the rules still leave most research peptides unapproved.
1 min readSafePeptideUse
A vial is only as trustworthy as its Certificate of Analysis
Research material is unregulated, so the label is a claim, not a guarantee. A recent third party Certificate of Analysis is the closest thing to proof you can get before you trust a vial.
1 min readSafePeptideUse